Galena Biopharma (NASDAQ: GALE) is down 6.5% after-hours Wednesday after the company said it received a "Paragraph IV" patent certification ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE